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Abstract
To examine the influence of maternal lymphocyte factors on the immune responses in offspring in early life, antibody production in
neonates born to either normal or lymphocyte-deficient mothers was analyzed. Recombination activating gene (Rag)-2+/ mouse neonates
born to Rag-2+/ +, Rag-2+/or Rag-2 / mothers were injected with goat anti-mouse IgD antiserum, and IgE and IgG1 production was
evaluated. The levels of IgE and IgG1 were higher in the pups born to Rag-2
+/ +and Rag-2+/ dams than to lymphocyte-deficient Rag-2 /
dams. The enhanced antibody production in the former compared with the latter neonates was also found following immunization with
ovalbumin or TNP-Ficoll. Thus, the presence of maternal lymphocyte factors was suggested in neonates that augmented antigen-specific
antibody production in both T cell-dependent and -independent pathways. A reduction in antibody production was observed in normal
neonates when they were foster-nursed by Rag-2 / mothers. Thus, the maternal lymphocyte factors enhancing the immune responses in
newborns were shown to be present in breast-milk.
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1. Introduction
It has been known that maternal factors transmitted to
offspring through the placenta during pregnancy and by
breast-feeding contribute to protection from infection. For
example, maternal immunoglobulins incorporated by neo-
nates efficiently function in their protection against the
pathogens surrounding them [1–3]. Newborns have acquired
an innate immunity to some degree [3], in addition, they are
able to produce antibodies upon antigen exposure, although
acquisition of full antigen responsiveness accompanied by
the diversification of the antibody repertoire is accomplished
after several months postpartum in humans [4–6]. It is
possible that maternal components transmitted to offspring
include certain factors involved in the augmentation of anti-
body production that are accompanied by substances working
as immunopotentiators for the innate immunity such as
vitamins, hormones, cytokines, growth factors, serum pro-
teins and oligosaccharides [1].
In this study, we focused our attention on the factors
secreted by maternal lymphocytes that enhance antibody
production in newborns. We found that immune responses
by neonatal mice born to or foster-nursed by lymphocyte-
deficient mothers were significantly weakened compared
with those by neonates born to and nursed by normal
mothers. Thus, maternal lymphocyte factors are speculated
to enhance the immune responses in newborns.
2. Materials and methods
2.1. Mice
C57BL/6 and recombination activating gene (Rag)-2-
deficient mice [7] with the C57BL/6 background were
purchased from Japan SLC (Shizuoka, Japan), and the
Jackson Laboratory (Bar Harbor, ME).
2.2. Immunogens and immunization of mice
Goat anti-mouse IgD antiserum [8] was provided by Dr. F.
Finkelman (University of Cincinnati Medical Center). Trini-
trophenyl (TNP)-conjugated Ficoll was provided by Dr. N.
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Shinohara (Kitasato University). Mice at 3 weeks of age were
intraperitoneally injected with either 200 Al of goat anti-
mouse IgD antiserum, 100 Ag of ovalbumin (OVA, Sigma, St.
Louis, MO) in 100 Al of PBS with 100 Al of Freund’s
complete adjuvant (Sigma), or 100 Ag of TNP-Ficoll in 200
Al of PBS [9], and were bled weekly.
2.3. Determination of serum immunoglobulin
The serum level of immunoglobulin was determined by
ELISA. For the determination of IgE and IgG1 in the serum
of goat anti-mouse IgD-treated mice, combinations of
monoclonal antibodies for coating and antigen detection
(biotin-labeled) (Serotec, Oxford, UK), and avidin perox-
ydase (Sigma) were used. OVA-specific IgG1 plasma anti-
bodies were determined as described in Ref. [10]. For
analyzing serum anti-TNP IgM following Ficoll-TNP
immunization, TNP-labeled BSA was used for coating and
a goat anti-mouse IgM F(abV)2 fragment conjugated with
pexoxydase (Jackson Immuno Research Laboratories, West
Grove, PA) for antigen detection. 3,3V,5,5V-tetramethylben-
zidine was used for color development, and absorbance at
450 nm under acidic conditions was determined with an EIA
reader (Model 2550, BioRad, Hercules, CA).
2.4. Typing of Rag-2-deficient mice
The genotype of Rag-2-deficient mice was determined by
PCR analysis using tail genomic DNA as a template. The
PCR primers used [11] were: (5VRag-2 primer) 5V-TTA ATT
CAA CCA GGC TTC TCA CCT-3V; (3VRag-2 primer) 5V-
GCC TGC TTA TTG TCT CCT GGT ATG-3V; (3V Neo
primer) 5V-CCA ACG CTA TGT CCT GAT AGC GGT-3V.
A pair of 5VRag-2 and 3VRag-2 primers were used to amplify
the Rag-2 gene, and a pair of 5VRag-2 and 3VNeo primers
were used to detect the targeting gene.
3. Results
3.1. Immune response of neonates born to normal and
lymphocyte-deficient mothers
Although the immune system of neonates is obviously
yet to mature, it has already acquired the ability to get rid
of surrounding foreign antigens to a certain degree. To
obtain evidence that maternal lymphocytes and/or their
factors influence the immune response in neonates, anti-
body production by neonates born to normal and lympho-
cyte-deficient mothers was compared upon antigen chal-
lenge. Functionally normal Rag-2+/ neonates (3 weeks of
age) born to Rag-2+/ +, Rag-2+/ or Rag-2 / mothers
were injected with goat antiserum against mouse IgD, a
polyclonal activator of the immune responses, and the
antigen production in serum was determined. Before treat-
ment, the serum IgE level was less than 100 ng/ml in each
subject. After 1 week, IgE levels reached more than 1000
ng/ml in 10 of the 13 neonates born to Rag-2+/ + or Rag-
Fig. 1. Antibody production in neonates born to normal or lymphocyte-deficient mothers. Rag-2+/ neonates (3 weeks of age) born to Rag-2+/ +, Rag-2+/ or
Rag-2 / mothers were injected with goat anti-mouse IgD antiserum, and then IgE production after 1 week (A), 2 weeks (B) and IgG1 production after 1 week (C)
in the serum was determined by ELISA. Each data-point represents a measurement taken from an individual subject. Bars in each column show the average level.
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2+/ mothers, compared to 6 of the 15 neonates born to
lymphocyte-deficient Rag-2 / dams (Fig. 1A). The aver-
age level of IgE production was much higher in the former
neonates than the latter (shown by bars in the figure). This
was also the case when the level of IgE was examined
after 2 weeks (Fig. 1B). An increase in antibody produc-
tion in the neonates born to Rag-2+/ + or Rag-2+/ mothers
was also observed when serum IgG1 levels were deter-
mined (Fig. 1C). These findings strongly suggest that
maternal lymphocyte factors enhanced the antibody pro-
duction in neonates.
Next, the antigen-specific production of immunoglobu-
lin in both T cell-dependent and -independent pathways
was compared among neonates born to normal and lym-
phocyte-deficient mothers. Rag-2+/ neonates (3 weeks of
age) born to Rag-2+/ + or Rag-2 / mothers were intra-
peritoneally immunized with OVA, and the serum level of
antigen-specific IgG1 produced by a T cell-dependent
mechanism was analyzed (Fig. 2). It was found that anti-
OVA IgG1 production after 2 weeks in the neonates born
to Rag-2+/ + mothers was greater than that in the neonates
born to Rag-2 / mothers. Then, neonates on the same
genetic backgrounds were immunized by TNP-Ficoll, and
the TNP-specific IgM produced in a T cell-independent
manner was determined (Fig. 3). The increased production
of the anti-TNP IgM in the serum of the neonates born to
Rag-2+/ + mothers was also observed after 1 week. There-
fore, maternal lymphocyte factors are suggested to be
involved in the augmentation of the antigen-specific anti-
body production in both T cell-dependent and -independent
pathways in early life.
3.2. Immune response in neonates nursed by lymphocyte-
deficient mothers
There are two independent pathways by which maternal
lymphocyte factors enter offspring to enhance immune
response, through the placenta during pregnancy and by
breast-feeding. To distinguish between the contributions of
Fig. 2. T cell-dependent antibody production in neonates born to normal or
lymphocyte-deficient mothers. Rag-2+/ neonates (3 weeks of age) born to
Rag-2+/ + or Rag-2 /  mothers were immunized with OVA and serum anti-
OVA IgG1 was analyzed by ELISA. Due to the unavailability of standard
anti-OVA IgG1, the IgG1 level is represented by an arbitrary unit
(absorption at 450 nm in ELISA). The results are the average for six to
eight animals.
Fig. 3. T cell-independent antibody production in neonates born to normal
or lymphocyte-deficient mothers. Rag-2+/ neonates (3 weeks of age) born
to Rag-2+/ + or Rag-2 / mothers were immunized with TNP-Ficoll and
serum anti-TNP IgM was determined by ELISA. The IgM level is
represented by an arbitrary unit (absorption at 450 nm in ELISA). The
results are the average for five to seven animals.
Fig. 4. Reduced immune responsiveness in genetically normal neonates fed
by lymphocyte-deficient mothers. Rag-2+/ + neonates immediately post-
partum were foster-nursed by a Rag-2 / mother that began nursing within
a few days of delivery. They were treated with goat anti-mouse IgD
antiserum at 3 weeks of age, and were bled weekly. The serum level of IgE
was determined by ELISA. As a control, neonates fed by a normal mother
were examined.
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these pathways, the immune response in normal neonates
nursed by either normal or lymphocyte-deficient mothers
was compared. Normal (Rag-2+/ +) neonates (3 weeks of
age) born to Rag-2+/ + mothers and those foster-nursed by
Rag-2 / mothers from just after birth were treated with
goat anti-mouse IgD antiserum, and the serum IgE level was
determined along with age (Fig. 4). Enhanced IgE produc-
tion was observed in the neonates nursed by normal mothers
compared with those nursed by lymphocyte-deficient moth-
ers, thus clearly indicating that maternal lymphocyte factors
enhancing the immune response of neonates are contained
in the breast-milk.
4. Discussion
In the present study, maternal lymphocyte-derived factors
were found to contribute to the immune response in neonates.
It is possible that a portion of the antibodies detected in
the immunized newborns originated from B cells trans-
mitted from the mother [12–15]. However, it is likely that
most of the antibodies found in the serum of the immunized
newborns were produced by their own immune system
because the repertoire of antigen specificity of the anti-
body-secreting B cells from the mother may be very limited.
Furthermore, a set of cognate antibody-secreting B cells,
helper T cells and antigen-presenting cells is required for the
T cell-dependent antibody production. Thus, maternal lym-
phocyte-derived soluble factors rather than transmitted
maternal lymphocytes themselves may contribute to anti-
body production by sensitizing the immune responsiveness
in neonates.
There are two routes by which maternal lymphocyte
factors can be transmitted to neonates. One of them is
through the placenta during pregnancy. It is known that
not only low molecular weight substances but also certain
proteins such as immunoglobulins, cytokines and hormones
are actively transferred through placenta. The other is the
route by breast-feeding. In milk, especially in colostrum,
immune-reactive factors including immunoglobulins and
trophic factors are abundant, and some of them are actively
incorporated on the epithelial layers of the intestine. These
two pathways differently contribute in individual mamma-
lian species. The presence of activators for neonatal immune
responses in breast-milk was demonstrated in this study
(Fig. 4). However, a contribution by the transplacental
pathway is also assumed since the significance of the
placental transfer of immunoglobulins has been demonstra-
ted in primates and to some extent in rodents [16].
The entity of the maternal lymphocyte factors vaccinating
the neonatal immune system is unclear. Possible candidates
include cytokines such as IL-4 and IL-13 or factors that
induce the secretion of these cytokines by the cells of
neonates and eventually promote their antibody production.
Another possible factor is maternal immunoglobulin, which
stimulates the immune system in an antigen-nonspecific
manner. A previous report suggesting the presence of a milk
IgG-dependent growth-promoting mechanism during early
neonatal life [17] supports this possibility. Alternatively,
supposed maternal lymphocyte factors may induce the
development and maturation of the immune-competent lym-
phocytes, and as a result, indirectly enhance the immune
responses in neonates. The discrimination of contributions
by maternal T and B lymphocytes may be helpful in
determining the factors enhancing neonatal immune respon-
siveness.
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